Skip to content

Incyte Corporation Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: October 29, 2026 results vs estimates

Incyte Corporation · E.INCY.NASDAQ · United States
Use symbol E.INCY.NASDAQ in our API & Excel add-in to retrieve this data ↓
116.80
(0.00%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum -50%
Trend 25%
Bubble Risk LOW
Realised Volatility (20D) 28.85%

Incyte Corporation Forecast

Incyte Corporation short-term momentum is negative (up over 1 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is positive (5 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 28.9% a year, a typical one-standard-deviation range is 112.05–121.55 over a week, 107.07–126.53 over a month and 83.10–150.50 over a year. (Signals as of 1 Nov 2026.)

Incyte Corporation Price Chart

MacroFinance.ai

Incyte Corporation Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Incyte Corporation
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Incyte Corporation
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Incyte Corporation
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Incyte Corporation
P/E
58.85x
Mid-range vs own history
QoQ +256.5%
YoY +240.2%
now 58.84613.77 low60.95 high
ⓘP/E As of 22 Nov 2026.See Incyte Corporation returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Incyte Corporation
P/S
3.95x
Mid-range vs own history
QoQ −13.6%
YoY −7.5%
now 3.94943.6 low4.57 high
ⓘP/S As of 22 Nov 2026.See Incyte Corporation returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Incyte Corporation
P/B
4.21x
Mid-range vs own history
QoQ +0.3%
YoY −4.8%
now 4.20693.55 low4.69 high
ⓘP/B As of 22 Nov 2026.See Incyte Corporation returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Incyte Corporation
EV/EBITDA
22.83x
Mid-range vs own history
QoQ +113.4%
YoY +117.4%
now 22.82538.41 low23.8 high
ⓘEV/EBITDA As of 22 Nov 2026.See Incyte Corporation returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Incyte Corporation
EV/Sales
3.31x
Mid-range vs own history
QoQ −12.8%
YoY −9.7%
now 3.31442.91 low3.94 high
ⓘEV/Sales As of 22 Nov 2026.See Incyte Corporation returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Incyte Corporation
FCF Yield
2.9%
Mid-range vs own history
QoQ −60.0%
YoY −50.5%
now 2.8852.79 low8.18 high
ⓘFCF Yield As of 22 Nov 2026.See Incyte Corporation returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Incyte Corporation
Earnings Yield
1.7%
Mid-range vs own history
QoQ −72.0%
YoY −70.6%
now 1.69941.64 low7.26 high
ⓘEarnings Yield As of 22 Nov 2026.See Incyte Corporation returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Incyte Corporation
Market Cap
$23.7B
Highest in 5 years
QoQ −10.8%
YoY +15.5%
now 23739.132818,490 low26,612 high
ⓘMarket Cap As of 22 Nov 2026.See Incyte Corporation returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Incyte Corporation
Net Debt
-$3.8B
Low vs own history
QoQ −15.1%
YoY +32.1%
now -3817.16-4,497 low-2,889 high
ⓘNet Debt As of 22 Nov 2026.See Incyte Corporation returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Incyte Corporation
Net Debt / EBITDA
-4.37x
Mid-range vs own history
QoQ +101.1%
YoY +154.7%
now -4.3734-4.37 low-1.72 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Incyte Corporation returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Incyte Corporation
Current Ratio
3.84x
Mid-range vs own history
QoQ −17.7%
YoY +20.2%
now 3.84013.2 low4.66 high
ⓘCurrent Ratio As of 22 Nov 2026.See Incyte Corporation returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Incyte Corporation
Quick Ratio
3.75x
Mid-range vs own history
QoQ −18.1%
YoY +19.6%
now 3.74673.13 low4.58 high
ⓘQuick Ratio As of 22 Nov 2026.See Incyte Corporation returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Incyte Corporation
Interest Coverage
341.70x
Mid-range vs own history
QoQ −59.7%
YoY −51.3%
now 341.6962341.7 low847.54 high
ⓘInterest Coverage As of 22 Nov 2026.See Incyte Corporation returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Incyte Corporation
Debt / Equity
0.01x
Low vs own history
QoQ +9.4%
YoY −25.6%
now 0.00660.01 low0.01 high
ⓘDebt / Equity As of 22 Nov 2026.See Incyte Corporation returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Incyte Corporation
Piotroski F-Score
6
Mid-range vs own history
QoQ 0.0%
YoY −25.0%
now 66 low8 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Incyte Corporation returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Incyte Corporation
Altman Z-Score
10.58
Strong vs own history
QoQ −18.2%
YoY +11.7%
now 10.58228.37 low12.94 high
ⓘAltman Z-Score As of 22 Nov 2026.See Incyte Corporation returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  19 members-only factors: Sloan Accruals, Cash-Earnings Gap, Days Sales in Receivables Index, Gross Margin Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Incyte Corporation, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Incyte Corporation fundamentals: income statement, balance sheet & cash flow

Incyte Corporation reported revenue of $5.14bn and net income of $1.29bn in FY2025, the year ended 31 December 2025 — revenue up 21.2% and net income up 3,845.0% on the prior year. Free cash flow was $1.35bn. These figures are as reported in the filings, not restated: 33 fiscal years and 133 quarters of history, back to December 1993. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$5.14bn
+21.2%
Net income
$1.29bn
+3,845.0%
Gross margin
92.76%
Free cash flow
$1.35bn
+443.9%
Net debt
-$3.06bn
Shares short (30 Oct 2026)
10.65m
5.58 days to cover
Incyte Corporation income statement, annual, as reported · USD millions unless stated
USD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue5,141.24,241.23,695.63,394.62,986.3
Cost of revenue372.1312.1255.0207.0151.0
Gross profit4,769.13,929.13,440.73,187.62,835.3
Research & development2,050.22,606.81,627.61,585.91,458.2
Selling, general & admin.1,376.21,222.01,161.31,002.1—
Operating income1,342.8101.3655.4591.6585.8
EBITDA1,760.2408.2919.4599.6630.2
Interest expense2.42.32.62.71.9
Pre-tax income1,664.5316.6834.2529.1570.4
Income tax377.8284.0236.6188.5-378.1
Net income1,286.732.6597.6340.7948.6

Download Incyte Corporation fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.INCY.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 33 fiscal years and 133 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Incyte Corporation

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Incyte Corporation Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Incyte Corporation; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Incyte Corporation’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Incyte Corporation behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Incyte Corporation (United States)

Incyte Corporation is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Incyte Corporation?
Incyte Corporation is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Incyte Corporation price?
The latest close is 116.8 (1 Nov 2026), -0.00% on the day. The price at the top of the page refreshes during the trading day.
Is Incyte Corporation in an uptrend?
As of 1 Nov 2026, short-term momentum is negative (1 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is positive (5 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Incyte Corporation?
20-day realised volatility is 28.9% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 8.3% over a month and 4.1% over a week.
What factors affect Incyte Corporation?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Incyte Corporation, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Incyte Corporation?
58 backtested tactical asset allocation strategies trade Incyte Corporation through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Incyte Corporation returns analysed?
The Statistical Distribution of Returns section shows the distribution of Incyte Corporation daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Incyte Corporation historical data?
In the Free historical data section of this page: the last 10 years of Incyte Corporation daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Incyte Corporation historical data (last 10 years)

Browse or instantly download the last 10 years of Incyte Corporation daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.INCY.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20114.625
2026-11-19115.87
2026-11-18117.8
2026-11-17119.09
2026-11-16120.27
2026-11-13120.97
2026-11-12121.7
2026-11-11122.27
2026-11-10120.3
2026-11-09121.89
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.